US20040087599A1 - cGMP-PDE inhibitors for the treatment of erectile dysfunction - Google Patents
cGMP-PDE inhibitors for the treatment of erectile dysfunction Download PDFInfo
- Publication number
- US20040087599A1 US20040087599A1 US10/694,644 US69464403A US2004087599A1 US 20040087599 A1 US20040087599 A1 US 20040087599A1 US 69464403 A US69464403 A US 69464403A US 2004087599 A1 US2004087599 A1 US 2004087599A1
- Authority
- US
- United States
- Prior art keywords
- disclosed
- patent application
- derivative
- european patent
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *C1=CC([5*])=C([4*])C=C1C1=NC2=C(C(=O)N1)C([2*])=NN2[1*] Chemical compound *C1=CC([5*])=C([4*])C=C1C1=NC2=C(C(=O)N1)C([2*])=NN2[1*] 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- This invention relates to the use of compounds which are selective inhibitors of cyclic guanosine 3′,5′-monophosphate phosphodiesterases (cGMP PDEs) in the treatment of erectile dysfunction (impotence) in male animals, including man.
- cGMP PDEs cyclic guanosine 3′,5′-monophosphate phosphodiesterases
- Impotence can be defined literally as a lack of power, in the male, to copulate and may involve an inability to achieve penile erection or ejaculation, or both. More specifically, erectile impotence or dysfunction may be defined as an inability to obtain or sustain an erection adequate for intercourse. Its prevalence is claimed to be between 2 and 7% of the human male population, increasing with age, up to 50 years, and between 18 and 75% between 55 and 80 years of age. In the USA alone, for example, it has been estimated that there are up to 10 million impotent males, with the majority suffering from problems of organic rather than of psychogenic origin.
- KCO Potassium channel openers
- VIP vasoactive intestinal polypeptide
- GTN glyceryl trinitrate
- This selective enzyme inhibition leads to elevated cGMP levels which, in turn, provides the basis for the utilities previously disclosed for the compounds in the treatment of stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, atherosclerosis, conditions of reduced blood vessel patency, peripheral vascular disease, stroke, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma, and diseases characterised by disorders of gut motility, e.g. irritable bowel syndrome.
- the specification goes on to describe investigations which identified three PDE isoenzymes in human corpus cavenosum tissue, relaxation of which leads to penile erection.
- the predominant enzyme was found to be the cGMP-specific PDE V , while cGMP-stimulated cAMP PDE II and cGMP-inhibited cAMP PDE III , were also present.
- the compounds described were found to be potent and selective inhibitors of the PDE V enzyme but demonstrated only weak inhibitory activity against the PDE II and PDE III enzymes. This activity is believed to be responsible for the action of the compounds in the treatment of erectile dysfunction.
- cGMP-PDE inhibitors have previously been described in the literature for a variety of utilities, these include use in treating obstructive lung diseases such as asthma and brochitis, in combatting allergic diseases such as allergic asthma, allergic rhinitis, urticaria, and irritable bowel syndrome; and in combatting angina, hypertension and congestive heart failure.
- Utility has also been claimed as diuretics, as antiinflammatory agents, in the treatment of baldness, for conditions of reduced blood vessel patency, and in glaucoma.
- any of these compounds would be of utility in the treatment of erectile dysfunction.
- the present invention provides the use of a compound which is a selective cGMP PDE inhibitor for the manufacture of a medicament for the treatment of erectile dysfunction in a male animal, including man, wherein said compound is:
- cGMP PDE inhibitors for use in the treatment of erectile dysfunction are:
- the compounds may be evaluated as selective inhibitors of cGMP-PDE using any of the methods previously described but in particular their activity against cGMP-PDE v may be assessed as described in our International patent application PCT/EP94/01580, (WO94/28902).
- oral administration is the preferred route, being the most convenient and avoiding the disadvantages associated with i.c. administration.
- a preferred dosing regimen for a typical man is 5 to 75 mg of compound daily, however the dosage may be increased depending on the potency of the compound being administered and higher dosages are within the scope of the invention.
- Alternative dosage regimes are also possible depending upon the individual patients circumstances such as the frequency of sexual intercourse.
- the drug may be administered parenterally, e.g. sublingually or buccally.
- a compound of the invention or a non-toxic salt thereof is administered as a suitably acceptable formulation in accordance with normal veterinary practice and the veterinary surgeon will determine the dosing regimen and route of administration which will be most appropriate for a particular male animal.
- the compounds of the invention are envisaged primarily for the treatment of erectile dysfunction or male sexual dysfunction, they are also useful for the treatment of female sexual dysfunction including orgasmic dysfunction related to clitoral disturbances, premature labour and dysmenorrhea.
- the invention also provides a method of treating erectile dysfunction in a male animal which comprises administering an effective amount of a compound which is a selective cGMP-PDE inhibitor as defined above.
- one of the groups of compounds of selective cGMP PDE inhibitors is a pyrazolopyrimidine derivative as disclosed in EP 0636626. This document discloses a compound of the formula:
- R 1 represents arylmethyl or C 1-6 alkyl optionally substituted by one or more fluorine atoms
- R 2 represents methyl
- R 3 represents C 2-4 alkyl
- R 4 represents nitro, cyano, C 1-6 alkoxy, C( ⁇ X)NR 6 R 7 , (CH 2 ) m NR 10 C( ⁇ Y)R 11 or a 5-membered heterocyclic ring selected from thienyl, thiazolyl and 1,2,4-triazolyl each ring optionally substituted by a C 1-4 alkyl or aryl group; or when R 1 is arylmethyl or C 1-6 alkyl substituted by one or more fluorine atoms then R 4 may also represent hydrogen;
- R 5 represents hydrogen or C 1-6 alkyl
- R 6 represents hydrogen or C 1-6 alkyl
- R 7 represents hydrogen, amino, hydroxyl, C 1-6 alkyl, aryl or arylC 1-4 alkyl;
- R 8 represents hydrogen or C 1-6 alkyl
- R 9 represents hydrogen, C 1-6 alkyl, SO 2 R 12 , CO 2 R 12 , C( ⁇ NCN)SR 12 or C( ⁇ NCN)NR 13 R 14 ;
- R 10 represents hydrogen or C 1-6 alkyl
- R 11 represents C 1-6 alkyl optionally substituted by one or more halogen atoms, or R 11 represents aryl, arylC 1-4 alkyl, thienyl, NR 15 R 16 , CH 2 NR 17 R 18 or R 10 and R 11 together represent A(CH 2 ) n —;
- R 12 represents C 1-6 alkyl, aryl or arylC 1-4 alkyl
- R 13 represents hydrogen or C 1-6 alkyl
- R 14 represents hydrogen, C 1-6 alkyl, aryl, arylC 1-4 alkyl or R 13 and R 14 together with the nitrogen atom to which they are attached form a morpholine, piperazine or N—C 1-4 alkylpiperazine ring;
- R 15 represent hydrogen or C 1-6 alkyl or R 10 and R 15 together represent—A(CH 2 ) n —;
- R 16 represents hydrogen, C 1-6 alkyl, aryl, arylC 1-4 alkyl, CO 2 R 12 , CH 2 CO 2 R 12 or R 15 and R 16 together with the nitrogen atom to which they are attached form a morpholine, piperazine or N—C 1-4 alkylpiperazine ring;
- R 17 represents hydrogen or C 1-6 alkyl
- R 18 represents hydrogen, C 1-6 alkyl, aryl, arylC 1-4 alkyl, COR 12 or R 17 and R 18 together with the nitrogen atom to which they are attached form a morpholine, piperazine or N—C 1-4 alkylpiperazine ring;
- A represents CH 2 or C ⁇ O
- m represents zero or 1
- n 1,2 or 3;
- X represents S or NH, or when R7 represents amino then X may also represent O;
- Y represents O or S.
Abstract
Pyrazolopyrimidine compounds which are selective inhibitors of cGMP PDE are useful in the treatment of erectile dysfunction (impotence) in male animals, including man.
Description
- This is a divisional application of application Ser. No. 09/880,141, which is a divisional application of application Ser. No. 08/836,670 filed May 22,1997, now U.S. Pat. No. 6,300,335 which is a National Phase filing under 35 USC § 371 based on PCT/EP95/04066 which was filed internationally on 16 Oct. 1995 and which was published internationally as WO 96/16644 on 6 Jun. 1996.
- This invention relates to the use of compounds which are selective inhibitors of cyclic guanosine 3′,5′-monophosphate phosphodiesterases (cGMP PDEs) in the treatment of erectile dysfunction (impotence) in male animals, including man.
- Impotence can be defined literally as a lack of power, in the male, to copulate and may involve an inability to achieve penile erection or ejaculation, or both. More specifically, erectile impotence or dysfunction may be defined as an inability to obtain or sustain an erection adequate for intercourse. Its prevalence is claimed to be between 2 and 7% of the human male population, increasing with age, up to 50 years, and between 18 and 75% between 55 and 80 years of age. In the USA alone, for example, it has been estimated that there are up to 10 million impotent males, with the majority suffering from problems of organic rather than of psychogenic origin.
- Reports of well-controlled clinical trials in man are few and the efficacy of orally administered drugs is low. Although many different drugs have been shown to induce penile erection, they are only effective after direct injection into the penis, e.g. intraurethrally or intracavernosally (i.c.), and are not approved for erectile dysfunction. Current medical treatment is based on the i.c. injection of vasoactive substances and good results have been claimed with phenoxybenzamine, phentolamine, papaverine and prostaglandin E1, either alone or in combination; however, pain, priapism and fibrosis of the penis are associated with the i.c. administration of some of these agents. Potassium channel openers (KCO) and vasoactive intestinal polypeptide (VIP) have also been shown to be active i.e., but cost and stability issues could limit development of the latter. An alternative to the i.c. route is the use of glyceryl trinitrate (GTN) patches applied to the penis, which has been shown to be effective but produces side-effects in both patient and partner.
- As a general alternative to pharmacological intervention, a variety of penile prostheses has been used to assist achievement of an erection. The short term success rate is good, but problems with infection and ischaemia, especially in diabetic men, make this type of treatment a final option rather than first-line therapy.
- According to the specification of our International patent application no PCT/EP94/01580, (publication no WO94/28902), we describe and claim the use of a series of pyrazolo [4,3-d]pyrimidin-7-ones for the treatment of impotence. The compounds are potent and selective inhibitors of cGMP PDE in contrast to their inhibition of cyclic adenosine 3′,5′-monophosphate phosphodiesterases (cAMP PDEs). This selective enzyme inhibition leads to elevated cGMP levels which, in turn, provides the basis for the utilities previously disclosed for the compounds in the treatment of stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, atherosclerosis, conditions of reduced blood vessel patency, peripheral vascular disease, stroke, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma, and diseases characterised by disorders of gut motility, e.g. irritable bowel syndrome. The specification goes on to describe investigations which identified three PDE isoenzymes in human corpus cavenosum tissue, relaxation of which leads to penile erection. The predominant enzyme was found to be the cGMP-specific PDEV, while cGMP-stimulated cAMP PDEII and cGMP-inhibited cAMP PDEIII, were also present. The compounds described were found to be potent and selective inhibitors of the PDEV enzyme but demonstrated only weak inhibitory activity against the PDEII and PDEIII enzymes. This activity is believed to be responsible for the action of the compounds in the treatment of erectile dysfunction.
- A number of cGMP-PDE inhibitors have previously been described in the literature for a variety of utilities, these include use in treating obstructive lung diseases such as asthma and brochitis, in combatting allergic diseases such as allergic asthma, allergic rhinitis, urticaria, and irritable bowel syndrome; and in combatting angina, hypertension and congestive heart failure. Utility has also been claimed as diuretics, as antiinflammatory agents, in the treatment of baldness, for conditions of reduced blood vessel patency, and in glaucoma. However there has not previously been any suggestion that any of these compounds would be of utility in the treatment of erectile dysfunction.
- Thus the present invention provides the use of a compound which is a selective cGMP PDE inhibitor for the manufacture of a medicament for the treatment of erectile dysfunction in a male animal, including man, wherein said compound is:
- i a 5-substituted pyrazolo [4,3-d]pyrimidine-7-one as disclosed in European patent application 0201188;
- ii a griseolic acid derivative as disclosed in European patent applications nos 0214708 and 0319050;
- iii a 2-phenylpurinone derivative as disclosed in European patent application 0293063;
- iv a phenylpyridone derivative as disclosed in European patent application 0347027;
- v a fused pyrimidine derivative as disclosed in European patent application 0347146;
- vi a condensed pyrimidine derivative as disclosed in European patent application 0349239;
- vii a pyrimidopyrimidine derivative as disclosed in European patent application 0351058;
- viii a purine compound as disclosed in European patent application 0352960;
- ix a quinazolinone derivative as disclosed in European patent application 0371731;
- x a phenylpyrimidone derivative as disclosed in European patent application 0395328;
- xi an imidazoquinoxalinone derivative or its aza analogue as disclosed in European patent application 0400583;
- xii a phenylpyrimidone derivative as disclosed in European patent application 0400799;
- xiii a phenylpyridone derivative as disclosed in European patent application 0428268;
- xiv a pyrimidopyrimidine derivative as disclosed in European patent 0442204;
- xv a 4-aminoquinazoline derivative as disclosed in European patent application 0579496;
- xvi a 4,5-dihydro4-oxo-pyrrolo[1,2-a]quinoxaline derivative or its aza analogue as disclosed in European patent application 0584487;
- xvii a polycyclic guanine derivative as disclosed in International patent application WO91/19717;
- xviii a nitrogenous heterocyclic compound as disclosed in International patent application WO93/07124;
- xix a 2-benzyl-polycyclic guanine derivative as disclosed in International patent application WO 94/19351;
- xx a quinazoline derivative as disclosed in U.S. Pat. No. 4,060,615;
- xxi a 6-heterocyclyl pyrazolo [3,4-d]pyrimidin4-one as disclosed in U.S. Pat. No. 5,294,612;
- xxii a benzimidazole as disclosed in Japanese patent application 5-222000; or
- xxiii a cycloheptimidazole as disclosed in European Journal of Pharmacology, 251, (1994), 1.
- xxiv a N-containing heterocycle as disclosed in International patent application WO94/22855.
- The invention includes the use of any compound within the scope of the claims of the patents listed above as well as the particular individual compounds disclosed therein.
- Of particular interest for use in the present invention are compounds disclosed in EP 0579496, WO93/07124, U.S. Pat. No. 5,294,612 and WO94/22855 (xv, xviii, xxi and xxiv above); the compounds of EP 0579496 and WO94/22855 being especially preferred.
- Examples of particular and preferred compounds from these patents and publications for use in the present invention include:
- 1,3-dimethyl-5-benzylpyrazolo[4,3-d]pyrimidine-7-one (preparation as described in European patent application 201188, Example 1),
- 2-(2-propoxyphenyl)-6-purinone (preparation as described in European patent application 0293063, Example 1),
- 6-(2-propoxyphenyl)-1,2-dihydro-2-oxopyridine-3-carboxamide (preparation as described in European patent application 0347027, Example 2),
- 2-(2-propoxyphenyl)pyrido[2,3-d]pyrimid-4(3H)-one (preparation as described in European patent application 0347146, Example 1),
- 7-methylthio-4-oxo-2-(2-propoxyphenyl)-3,4-dihydropyrimido[4,5-d]pyrimidine (preparation as described in European patent application 0351058, Example 1),
- 6-hydroxy-2-(2-propoxyphenyl)pyrimidine4-carboxamide (preparation as described in European patent application 0395328, Example 15),
- 1-ethyl-3-methylimidazo[1,5a]quinoxalin-4(5H)-one (preparation as described in European patent application 0400583),
- 4-phenylmethylamino-6-chloro-2-(1-imidazoloyl)quinazoline (preparation as described in European patent application 0579496, Example 5(c)),
- 5-ethyl-8-[3-(N-cyclohexyl-N-methylcarbamoyl)-propyloxy]4,5-dihydro-4-oxo-pyrido[3,2-e]pyrrolo[1,2-a]pyrazine (preparation as described in European patent application 0584487, Example 1),
- 5′-methyl-3′-(phenylmethyl)-spiro[cyclopentane-1,7′(8′H)-(3′H)-imidazo[2,1-b]purin]4′(5′H)-one (preparation as described in International patent application WO 91/19717, Example 9A3),
- 1-[6-chloro-4-(3,4-methylenedioxybenzyl)aminoquinazolin-2-yl)piperidine-4-carboxylic acid (preparation as described in International patent application WO93/07124),
- (6aR,9aS)-2-(4-trifluoromethylphenyl)methyl-5-methyl-3,4,5,6a,7,8,9,9a-octahydrocyclopent[4,5]imidazo[2,1-b]purin-4-one(preparation as described in International Patent application WO94/19351, Example 14),
- 1-tert-butyl-3-phenylmethyl-6-(4-pyridyl)pyrazolo[3,4-d] pyrimid-4-one (preparation as described in U.S. Pat. No. 5,294,612, Example 90),
- 1-cyclopentyl-3-methyl-6-(4-pyridyl)-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimid-4-one, (preparation as described in U.S. Pat. No. 5,294,612, Example 83),
- 2-butyl-1-(2-chlorobenzyl)6-ethoxycarbonylbenzimidazole (preparation described in Japanese patent application 5-222000),
- 2-(4-carboxypiperidino)-4-(3,4-methylenedioxybenzyl)amino-6-nitroquinazoline (preparation described in International patent application WO94/22855, Example II),
- and 2-phenyl-8-ethoxycycloheptimidazole (KT2-734).
- Of particular interest for use in the present invention are the compounds:
- 4-phenylmethylamino-6-chloro-2-(1-imidazoloyl)quinazoline (preparation as described in European patent application 0579496, Example 5(c)),
- 1-[6-chloro-4-(3,4-methylenedioxybenzyl)aminoquinazolin-2-yl)piperidine-4-carboxylic acid (preparation as described in International patent application WO93/07124),
- (6aR,9aS)-2-(4-trifluoromethylphenyl)methyl-5-methyl-3,4,5,6a,7,8,9,9a-octahydrocyclopent[4,5]imidazo[2,1-b]purin-4-one(preparation as described in International Patent application WO94/19351, Example 14),
- 1-tert-butyl-3-phenylmethyl-6-(4-pyridyl)pyrazolo[3,4-d]pyrimid-4-one (preparation as described in U.S. Pat. No. 5,294,612, Example 90),
- 1-cyclopentyl-3-methyl-6-(4-pyridyl)-4,5-dihydro-1H-pyrazolo[3,4-d] pyrimid-4-one, as described in U.S. Pat. No. 5,294,612, Example 83), or
- 2-(4-carboxypiperidino)-4-(3,4-methylenedioxybenzyl)amino-6-nitroquinazoline (preparation described in International patent application WO94/22855, Example II),
- Further cGMP PDE inhibitors for use in the treatment of erectile dysfunction are:
- xxv a pyrazolopyrimidine derivative as disclosed in European patent application 0636626;
- xxvi a 4-aminopyrimidine derivative as disclosed in European patent application 0640599;
- xxvii a imidazoquinazoline derivative as disclosed in International patent application WO95/06648;
- xxviii an anthranilic acid derivative as disclosed in International patent application WO95/18097;
- xxix a 4-aminoquinazoline derivative as disclosed in U.S. Pat. No. 5,436,233;
- xxx a tetracyclic derivative as disclosed in International patent application WO95/19978;
- xxxi a imidazoquinazoline derivative as disclosed in European patent application 0668280; or
- xxxii a quinazoline compound as disclosed in European patent application 0669324.
- The compounds may be evaluated as selective inhibitors of cGMP-PDE using any of the methods previously described but in particular their activity against cGMP-PDEv may be assessed as described in our International patent application PCT/EP94/01580, (WO94/28902).
- Generally, in man, oral administration is the preferred route, being the most convenient and avoiding the disadvantages associated with i.c. administration. A preferred dosing regimen for a typical man is 5 to 75 mg of compound daily, however the dosage may be increased depending on the potency of the compound being administered and higher dosages are within the scope of the invention. Alternative dosage regimes are also possible depending upon the individual patients circumstances such as the frequency of sexual intercourse. In circumstances where the recipient suffers from a swallowing disorder or from impairment of drug absorption after oral administration, the drug may be administered parenterally, e.g. sublingually or buccally.
- For veterinary use, a compound of the invention or a non-toxic salt thereof is administered as a suitably acceptable formulation in accordance with normal veterinary practice and the veterinary surgeon will determine the dosing regimen and route of administration which will be most appropriate for a particular male animal.
- Although the compounds of the invention are envisaged primarily for the treatment of erectile dysfunction or male sexual dysfunction, they are also useful for the treatment of female sexual dysfunction including orgasmic dysfunction related to clitoral disturbances, premature labour and dysmenorrhea.
- The invention also provides a method of treating erectile dysfunction in a male animal which comprises administering an effective amount of a compound which is a selective cGMP-PDE inhibitor as defined above.
-
- and salts and solvates (e.g. hydrates) thereof, in which:
- R1 represents arylmethyl or C1-6alkyl optionally substituted by one or more fluorine atoms;
- R2 represents methyl;
- R3 represents C2-4alkyl;
- R4 represents nitro, cyano, C1-6alkoxy, C(═X)NR6R7, (CH2)mNR10C(═Y)R11 or a 5-membered heterocyclic ring selected from thienyl, thiazolyl and 1,2,4-triazolyl each ring optionally substituted by a C1-4alkyl or aryl group; or when R1 is arylmethyl or C1-6alkyl substituted by one or more fluorine atoms then R4 may also represent hydrogen;
- R5 represents hydrogen or C1-6alkyl;
- R6 represents hydrogen or C1-6alkyl;
- R7 represents hydrogen, amino, hydroxyl, C1-6alkyl, aryl or arylC1-4alkyl;
- R8 represents hydrogen or C1-6alkyl;
- R9 represents hydrogen, C1-6alkyl, SO2R12, CO2R12, C(═NCN)SR12 or C(═NCN)NR13R14;
- R10 represents hydrogen or C1-6alkyl;
- R11 represents C1-6alkyl optionally substituted by one or more halogen atoms, or R11 represents aryl, arylC1-4alkyl, thienyl, NR15R16, CH2NR17R18 or R10 and R11 together represent A(CH2)n—;
- R12 represents C1-6alkyl, aryl or arylC1-4alkyl;
- R13 represents hydrogen or C1-6alkyl;
- R14 represents hydrogen, C1-6alkyl, aryl, arylC1-4alkyl or R13 and R14 together with the nitrogen atom to which they are attached form a morpholine, piperazine or N—C1-4alkylpiperazine ring;
- R15 represent hydrogen or C1-6alkyl or R10 and R15 together represent—A(CH2)n—;
- R16 represents hydrogen, C1-6alkyl, aryl, arylC1-4alkyl, CO2R12, CH2CO2R12 or R15 and R16 together with the nitrogen atom to which they are attached form a morpholine, piperazine or N—C1-4alkylpiperazine ring;
- R17 represents hydrogen or C1-6alkyl;
- R18 represents hydrogen, C1-6alkyl, aryl, arylC1-4alkyl, COR12 or R17 and R18 together with the nitrogen atom to which they are attached form a morpholine, piperazine or N—C1-4alkylpiperazine ring;
- A represents CH2 or C═O;
- m represents zero or 1;
- n represents 1,2 or 3;
- X represents S or NH, or when R7 represents amino then X may also represent O;
- Y represents O or S.
- The reader is referred to the original European patent document for a complete discussion and disclosure of syntheses, representative compounds, and so forth, falling within its scope.
Claims (7)
1. The use of a compound which is a selective cGMP PDE inhibitor for the manufacture of a medicament for the treatment of erectile dysfunction in a male animal, including man, wherein said compound is:
i a 5-substituted pyrazolo[4,3-d]pyrimdine-7-one as disclosed in European patent application 0201188;
ii a griseolic acid derivative as disclosed in European patent applications nos 0214708 and 0319050;
iii a 2-phenylpurinone derivative as disclosed in European patent application 0293063;
iv a phenylpyridone derivative as disclosed in European patent application 0347027;
v a fused pyrimidine derivative as disclosed in European patent application 0347146;
vi a condensed pyrimidine derivative as disclosed in European patent application 0349239;
vii a pyrimidopyrimidine derivative as disclosed in European patent application 0351058;
viii a purine compound as disclosed in European patent application 0352960;
ix a quinazolinone derivative as disclosed in European patent application 0371731;
x a phenylpyrimidone derivative as disclosed in European patent application 0395328;
xi an imidazoquinoxalinone derivative or its aza analogue as disclosed in European patent application 0400583;
xii a phenylpyrimidone derivative as disclosed in European patent application 0400799;
xiii a phenylpyridone derivative as disclosed in European patent application 0428268;
xiv a pyrimidopyrimidine derivative as disclosed in European patent 0442204;
xv a 4-aminoquinazoline derivative as disclosed in European patent application 0579496;
xvi a 4,5-dihydro4-oxo-pyrrolo[1,2-a]quinoxaline derivative or its aza analogue as disclosed in European patent application 0584487;
xvii a polycyclic guanine derivative as disclosed in International patent application WO91/19717;
xviii a nitrogenous heterocyclic compound as disclosed in International patent application WO93/07124;
xix a 2-benzyl-polycyclic guanine derivative as disclosed in International patent application WO 94/19351;
xx a quinazoline derivative as disclosed in U.S. Pat. No. 4,060,615
xxi a 6-heterocyclyl pyrazolo[3,4-d]pyrimidin-4-one as disclosed in U.S. Pat. No. 5,294,612
xxii a benzimidazole as disclosed in Japanese patent application 5-222000; or xxiii a cycloheptimidazole as disclosed in European Journal of Pharmacology, 251, (1994), 1.
xxiv a N-containing heterocycle as disclosed in International patent application WO94/22855.
2. The use of a compound as claimed in claim 1 wherein said compound is:
a 4-aminoquinazoline derivative as disclosed in European patent application 0579496;
a nitrogenous heterocyclic compound as disclosed in International patent application WO93/07124;
a 6-heterocyclyl pyrazolo[3,4-d]pyrimid-4-one as disclosed in U.S. Pat. No. 5,294,612 or
a N-containing heterocycle as disclosed in International patent application WO94/22855.
3. The use of a compound as claimed in claim 1 wherein said compound is:
1,3-dimethyl-5-benzylpyrazolo[4,3-d]pyrimidine-7-one;
2-(2-propoxyphenyl)-6-purinone;
6-(2-propoxyphenyl)-1,2-dihydro-2-oxopyridine-3-carboxamide;
2-(2-propoxyphenyl)pyrido[2,3-d]pyrimid4(3H)-one;
7-methylthio-4-oxo-2-(2-propoxyphenyl)-3,4-dihydropyrimido[4,5-d]pyrimidine;
6-hydroxy-2-(2-propoxyphenyl)pyrimidine-4-carboxamide;
1-ethyl-3-methylimidazo[1,5a]quinoxalin-4(5H)-one;
4-phenylmethylamino-6-chloro-2-(1-imidazoloyl)quinazoline;
5-ethyl-8-[3-(N-cyclohexyl-N-methylcarbamoyl)-propyloxy]-4,5-dihydro4-oxo-pyrido[3,2-e]pyrrolo[1,2-a]pyrazine;
5′-methyl-3′-(phenylmethyl)-spiro[cyclopentane-1,7′(8′H)-(3′H)-imidazo[2,1-b]purin]4′(5′H)-one
1-[6-chloro-4-(3,4-methylenedioxybenzyl)aminoquinazolin-2-yl)piperidine4-carboxylic acid;
(6aR,9aS)-2-(4-trifluoromethylphenyl)methyl-5-methyl-3,4,5,6a,7,8,9,9a-octahydrocyclopent[4,5]imidazo[2,1-b]purin-4-one;
1-tert-butyl-3-phenylmethyl-6-(4-pyridyl)pyrazolo[3,4-d]pyrimid-4-one;
1-cyclopentyl-3-methyl-6-(4-pyridyl)4,5-dihydro- 1H-pyrazolo[3,4-d]pyrimid4-one;
2-butyl-1-(2-chlorobenzyl)6-ethoxycarbonylbenzimidazole;
2-(4-carboxypiperidino)-4-(3,4-methylenedioxybenzyl)amino-6-nitroquinazoline; or 2-phenyl-8-ethoxycycloheptimidazole.
4. The use of a compound as claimed in claim 3 where said compound is:
4-phenylmethylamino-6-chloro-2-(1-imidazoloyl)quinazoline;
1-[6-chloro-4-(3,4-methylenedioxybenzyl)aminoquinazolin-2-yl)piperidine-4-carboxylic acid;
(6aR,9aS)-2-(4-trifluoromethylphenyl)methyl-5-methyl-3,4,5,6a,7,8,9,9a-octahydrocyclopent[4,5]imidazo[2,1-b]purin-4-one;
1-tert-butyl-3-phenylmethyl-6-(4-pyridyl)pyrazolo[3,4-d]pyrimid4-one;
1-cyclopentyl-3-methyl-6-(4-pyridyl)4 ,5-dihydro-1H-pyrazolo[3,4-d]pyrimid-4-one; or
2-(4-carboxypiperidino)-4-(3,4-methylenedioxybenzyl)amino-6-nitroquinazoline;
5. The use of a compound which is a selective cGMP PDE inhibitor for the manufacture of a medicament for the treatment of erectile dysfunction in a male animal, including man, wherein said compound is:
xxv a pyrazolopyrimidine derivative as disclosed in European patent application 0636626;
xxvi a 4-aminopyrimidine derivative as disclosed in European patent application 0640599;
xxvii a imidazoquinazoline derivative as disclosed in International patent application WO95/06648;
xxviii an anthranilic acid derivative as disclosed in International patent application WO95/18097;
xxix a 4-aminoquinazoline derivative as disclosed in U.S. Pat. No. 5,436,233;
xxx a tetracyclic derivative as disclosed in International patent application WO95/19978;
xxxi a imidazoquinazoline derivative as disclosed in European patent application 0668280; or
xxxii a quinazoline compound as disclosed in European patent application 0669324.
6. The use of a compound which is a selective cGMP PDE inhibitor for the manufacture of a medicament for the curative or prophylactic treatment of female sexual dysfunction, premature labour or dysmenorrhea, wherein said compound is a compound as previously claimed in any one of claims 1 to 5 for use in the treatment of erectile dysfunction in a male.
7. A method for the treatment of erectile dysfunction in a male animal or female sexual dysfunction, premature labour or dysmenorrhea, which comprises administering an effective amount of a compound which is a selective cGMP PDE inhibitor as previously claimed in any one of claims 1 to 5 .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/694,644 US20040087599A1 (en) | 1994-11-26 | 2003-10-27 | cGMP-PDE inhibitors for the treatment of erectile dysfunction |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9423910A GB9423910D0 (en) | 1994-11-26 | 1994-11-26 | Therapeutic agents |
GB9423910.0 | 1994-11-26 | ||
US08/836,670 US6300335B1 (en) | 1994-11-26 | 1995-10-16 | 4-aminoquinazoline derivative cGMP-PDE inhibitors for the treatment of erectile dysfunction |
US09/880,141 US6656945B2 (en) | 1994-11-26 | 2001-06-13 | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one cGMP-PDE inhibitors for the treatment of erectile dysfunction |
US10/694,644 US20040087599A1 (en) | 1994-11-26 | 2003-10-27 | cGMP-PDE inhibitors for the treatment of erectile dysfunction |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/880,141 Division US6656945B2 (en) | 1994-11-26 | 2001-06-13 | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one cGMP-PDE inhibitors for the treatment of erectile dysfunction |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040087599A1 true US20040087599A1 (en) | 2004-05-06 |
Family
ID=10765031
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/836,670 Expired - Lifetime US6300335B1 (en) | 1994-11-26 | 1995-10-16 | 4-aminoquinazoline derivative cGMP-PDE inhibitors for the treatment of erectile dysfunction |
US09/880,141 Expired - Lifetime US6656945B2 (en) | 1994-11-26 | 2001-06-13 | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one cGMP-PDE inhibitors for the treatment of erectile dysfunction |
US10/694,644 Abandoned US20040087599A1 (en) | 1994-11-26 | 2003-10-27 | cGMP-PDE inhibitors for the treatment of erectile dysfunction |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/836,670 Expired - Lifetime US6300335B1 (en) | 1994-11-26 | 1995-10-16 | 4-aminoquinazoline derivative cGMP-PDE inhibitors for the treatment of erectile dysfunction |
US09/880,141 Expired - Lifetime US6656945B2 (en) | 1994-11-26 | 2001-06-13 | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one cGMP-PDE inhibitors for the treatment of erectile dysfunction |
Country Status (7)
Country | Link |
---|---|
US (3) | US6300335B1 (en) |
EP (1) | EP0793486A1 (en) |
JP (3) | JP2975990B2 (en) |
FI (1) | FI972205A0 (en) |
GB (1) | GB9423910D0 (en) |
MX (1) | MX9703868A (en) |
WO (1) | WO1996016644A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070010450A1 (en) * | 2003-06-13 | 2007-01-11 | Microbia, Inc., A Massachusetts Corporation | Methods and compositions for the treatment of gastrointestinal disorders |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060222647A1 (en) * | 1993-05-27 | 2006-10-05 | Beavo Joseph A | Methods and compositions for modulating the activity of PDE5 |
GB9311920D0 (en) | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
GB9423910D0 (en) * | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
CA2189355A1 (en) * | 1995-03-01 | 1996-09-06 | Yasuo Onoda | Imidazoquinazoline derivatives |
US5718917A (en) * | 1995-12-15 | 1998-02-17 | Harvard Scientific Corporation | PGE-1 containing lyophilized liposomes for use in the treatment of erectile dysfunction |
HUP9900625A3 (en) * | 1995-12-28 | 2003-04-28 | Fujisawa Pharmaceutical Co | Benzimidazole derivatives, pharmaceutical compositions containing them and process for preparing the compounds |
WO1998007430A1 (en) * | 1996-08-20 | 1998-02-26 | Eisai Co., Ltd. | Remedy for erection failure comprising fused pyridazine compound |
US6331543B1 (en) * | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
US20020118296A1 (en) * | 1999-05-06 | 2002-08-29 | Schwab Barry H. | Integrated multi-format audio/video production system |
US6370198B1 (en) * | 1997-04-07 | 2002-04-09 | Kinya Washino | Wide-band multi-format audio/video production system with frame-rate conversion |
IL132276A0 (en) | 1997-04-25 | 2001-03-19 | Pfizer | Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cgmp pde5) for the treatment of sexual dysfunction |
TW453999B (en) | 1997-06-27 | 2001-09-11 | Fujisawa Pharmaceutical Co | Benzimidazole derivatives |
US6103765A (en) | 1997-07-09 | 2000-08-15 | Androsolutions, Inc. | Methods for treating male erectile dysfunction |
AU742787B2 (en) | 1997-07-09 | 2002-01-10 | Androsolutions, Inc. | Improved methods and compositions for treating male erectile dysfunction |
US6593369B2 (en) | 1997-10-20 | 2003-07-15 | Vivus, Inc. | Methods, compositions, and kits for enhancing female sexual desire and responsiveness |
GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
US6037346A (en) * | 1997-10-28 | 2000-03-14 | Vivus, Inc. | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
US20020099003A1 (en) * | 1997-10-28 | 2002-07-25 | Wilson Leland F. | Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof |
CA2306837C (en) | 1997-10-28 | 2007-05-08 | Asivi, Llc. | Treatment of female sexual dysfunction |
US6548490B1 (en) | 1997-10-28 | 2003-04-15 | Vivus, Inc. | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
US6403597B1 (en) | 1997-10-28 | 2002-06-11 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
CA2305394C (en) * | 1997-10-28 | 2006-12-12 | Vivus, Incorporated | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
US6127363A (en) * | 1997-10-28 | 2000-10-03 | Vivus, Inc. | Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction |
US6156753A (en) * | 1997-10-28 | 2000-12-05 | Vivus, Inc. | Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction |
ZA9810766B (en) | 1997-11-28 | 1999-05-25 | Mochida Pharm Co Ltd | Novel compounds having cgmp-pde inhibitory activity |
WO1999043674A1 (en) * | 1998-02-27 | 1999-09-02 | Kyowa Hakko Kogyo Co., Ltd. | Remedies for erectile dysfunction |
ATE247117T1 (en) | 1998-04-20 | 2003-08-15 | Pfizer | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL FUNCTION DISORDERS |
JP4717210B2 (en) * | 1998-09-04 | 2011-07-06 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 5-heterocyclylpyrazolo [4,3-d] pyrimidin-7-one for the treatment of male erectile dysfunction |
GB9823103D0 (en) | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
GB9823101D0 (en) | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
GB9823102D0 (en) | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
GB9828340D0 (en) * | 1998-12-22 | 1999-02-17 | Novartis Ag | Organic compounds |
JP2002540102A (en) * | 1999-03-22 | 2002-11-26 | ブリストル−マイヤーズ スクイブ カンパニー | Condensed pyridopyridazine inhibitors of cGMP phosphodiesterase |
DE19944161A1 (en) * | 1999-09-15 | 2001-03-22 | Bayer Ag | New combination for the treatment of sexual dysfunction |
EA200200240A1 (en) * | 1999-10-11 | 2002-10-31 | Пфайзер Инк. | 5- (2-SUBSTITUTED-5-HETEROCYCLILESULPHONYLPYRID-3-IL) -DIGIDROPYRAZOLO [4,3-d] PYRIMIDIN-7-ONE AS PHYSPHODESTERASE INHIBITORS |
TWI265925B (en) | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
US6476037B1 (en) | 2000-03-23 | 2002-11-05 | The Regents Of The University Of California | L-arginine and phosphodiesterase (PDE) inhibitor synergism |
UA74826C2 (en) | 2000-05-17 | 2006-02-15 | Ortho Mcneil Pharm Inc | ?-carboline derivatives as phosphodiesterase inhibitors |
PE20020394A1 (en) | 2000-08-18 | 2002-06-21 | Agouron Pharma | PIRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, MODULATE AND / OR INHIBIT THE ACTIVITY OF ERAB / HADH2 |
US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
US6821978B2 (en) | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
KR100540623B1 (en) | 2001-02-26 | 2006-01-11 | 다나베 세이야꾸 가부시키가이샤 | Pyridopyrimidine or naphthyridine derivative |
EP1442042A1 (en) | 2001-11-09 | 2004-08-04 | Schering Corporation | Polycyclic guanine derivative phosphodiesterase v inhibitors |
US20090035221A1 (en) * | 2002-01-25 | 2009-02-05 | Ramsey Sallis | Methods and Compositions for Treatment of Erectile Dysfunction |
WO2003063776A2 (en) | 2002-01-25 | 2003-08-07 | Modular Properties Ltd | Methods and compositions for treating male erectile dysfunction |
US20090257956A1 (en) * | 2002-01-25 | 2009-10-15 | Ramsey Sallis | Treatment Method for Treatment of Erectile Dysfunction and Premature Ejaculation |
US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
US7276529B2 (en) * | 2002-03-20 | 2007-10-02 | Celgene Corporation | Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
US7208516B2 (en) * | 2002-03-20 | 2007-04-24 | Celgene Corporation | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
MXPA04009997A (en) * | 2002-04-12 | 2004-12-13 | Celgene Corp | Modulation of stem and progenitor cell differentiation, assays, and uses thereof. |
KR20050000398A (en) * | 2002-04-12 | 2005-01-03 | 셀진 코포레이션 | Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds |
DE10238722A1 (en) * | 2002-08-23 | 2004-03-11 | Bayer Ag | Improving attention, concentration, cognition, learning and/or memory performance, using selective phosphodiesterase 9A inhibitors, preferably 4H-pyrazolo-(3,4-d)-pyrimidin-4-one derivatives |
DE10238723A1 (en) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl substituted pyrazolyprimidines |
DE10238724A1 (en) * | 2002-08-23 | 2004-03-04 | Bayer Ag | New 6-alkyl-1,5-dihydro-4H-pyrazolo-(3,4-d)-pyrimidin-4-ones useful as selective phosphodiesterase 9A inhibitors for improving attention, concentration, learning and/or memory performance |
DE10320785A1 (en) * | 2003-05-09 | 2004-11-25 | Bayer Healthcare Ag | 6-arylmethyl substituted pyrazolopyrimidines |
DE102004001873A1 (en) * | 2004-01-14 | 2005-09-29 | Bayer Healthcare Ag | Cyanopyrimidinone |
US7700608B2 (en) | 2004-08-04 | 2010-04-20 | Shire Holdings Ag | Quinazoline derivatives and their use in the treatment of thrombocythemia |
US20060030574A1 (en) | 2004-08-04 | 2006-02-09 | Shire Holdings Ag | Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
CA2620333A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
CA2625153A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
EP1942879A1 (en) | 2005-10-31 | 2008-07-16 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
NZ568694A (en) | 2005-11-09 | 2011-09-30 | Zalicus Inc | Method, compositions, and kits for the treatment of medical conditions |
US20070155791A1 (en) * | 2005-12-29 | 2007-07-05 | Zeldis Jerome B | Methods for treating cutaneous lupus using aminoisoindoline compounds |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
JP2009536669A (en) | 2006-05-09 | 2009-10-15 | ブレインセルス,インコーポレイティド | Neurogenesis by angiotensin regulation |
KR20080015594A (en) * | 2006-08-16 | 2008-02-20 | 주식회사종근당 | Quinazoline derivative as phosphodiesterase inhibitor and a process for preparing the same |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
US7910597B2 (en) | 2006-11-28 | 2011-03-22 | Shire Llc | Substituted quinazolines |
DE102007028869A1 (en) | 2007-06-22 | 2008-12-24 | Ratiopharm Gmbh | A process for the preparation of a medicament containing tadalafil |
PE20091211A1 (en) * | 2007-11-30 | 2009-09-14 | Boehringer Ingelheim Int | PYRAZOLOPYRIMIDINE DERIVATIVES AS PDE9A MODULATORS |
JP2011515469A (en) * | 2008-03-24 | 2011-05-19 | セルジーン コーポレイション | Psoriasis using cyclopropyl-N- {2-[(1S) -1- (3-ethoxy-4-methoxyphenyl) -2- (methylsulfonyl) ethyl] -3-oxoisoindoline-4-yl} carboxamide Or treatment of psoriatic arthritis |
UA105362C2 (en) * | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
NZ590788A (en) | 2008-09-08 | 2012-11-30 | Boehringer Ingelheim Int | Pyrazolopyrimidines and their use for the treatment of cns disorders |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
MA33152B1 (en) * | 2009-03-31 | 2012-03-01 | Boehringer Ingelheim Int | 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO [3,4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS MODULATORS OF PDE9A |
US20100261737A1 (en) * | 2009-04-10 | 2010-10-14 | Medtronic Vascular, Inc. | Method of Treating Erectile Dysfunction |
DE102009033396A1 (en) | 2009-07-16 | 2011-01-20 | Ratiopharm Gmbh | An aqueous solution and gelatinized composition comprising a phosphodiesterase 5 inhibitor and methods and use thereof |
DE102009035211A1 (en) | 2009-07-29 | 2011-02-17 | Ratiopharm Gmbh | A coprecipitate comprising a phosphodiesterase-5 inhibitor (PDE-5 inhibitor) and a pharmaceutically acceptable carrier, their preparation and use |
AR077859A1 (en) * | 2009-08-12 | 2011-09-28 | Boehringer Ingelheim Int | COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS |
CN103052639B (en) | 2010-08-12 | 2016-02-17 | 贝林格尔.英格海姆国际有限公司 | 6-cycloalkyl-1,5-dihydro-pyrazol is [3,4-d] pyrimidin-4-one-derivatives and the purposes as PDE9A inhibitor thereof also |
TW201210584A (en) | 2010-08-18 | 2012-03-16 | Alcon Res Ltd | Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma |
US8809345B2 (en) | 2011-02-15 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders |
WO2013067309A1 (en) | 2011-11-04 | 2013-05-10 | Xion Pharmaceutical Corporation | Methods and compositions for oral administration of melanocortin receptor agonist compounds |
US20150119399A1 (en) | 2012-01-10 | 2015-04-30 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
EP3157520B1 (en) | 2014-06-23 | 2019-09-04 | Celgene Corporation | Apremilast for the treatment of a liver disease or a liver function abnormality |
BR112022025238A2 (en) | 2020-06-11 | 2023-02-14 | Chdi Foundation Inc | HETEROCYCLIC COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEIN |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4521421A (en) * | 1983-09-26 | 1985-06-04 | Eli Lilly And Company | Treatment of sexual dysfunction |
US5436233A (en) * | 1992-07-15 | 1995-07-25 | Ono Pharmaceutical Co., Ltd. | 4-aminoquinazoline derivatives |
US6407114B1 (en) * | 1998-10-23 | 2002-06-18 | Pfizer Inc. | Pyrazolopyrimidinone CGMP PDE5 inhibitors for the treatment of sexual dysfunction |
US6656945B2 (en) * | 1994-11-26 | 2003-12-02 | Pfizer Inc | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one cGMP-PDE inhibitors for the treatment of erectile dysfunction |
US6723719B1 (en) * | 1997-04-25 | 2004-04-20 | Pfizer Inc | Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′—monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2547501A1 (en) | 1983-06-15 | 1984-12-21 | Opochimiotherapie Lab | Alkaline-earth metal-free effervescent excipient containing carbonate compounds of arginine and an acid, and corresponding effervescent tablets |
CA1303037C (en) | 1987-02-02 | 1992-06-09 | Smith Kline & French Laboratories Limited | Purinone derivatives as bronchodilators vasodilators and anti-allergic agents |
IT1217190B (en) | 1988-04-22 | 1990-03-14 | Recordati Chem Pharm | USEFUL COMPOUNDS FOR THE TREATMENT AND DIAGNOSIS OF HURRY DYSFUNCTIONS |
GB8827988D0 (en) * | 1988-11-30 | 1989-01-05 | Smith Kline French Lab | Chemical compounds |
JPH0344324A (en) | 1989-07-13 | 1991-02-26 | Kazuoki Tsuchiya | Sexual function invigorator |
GB8928346D0 (en) | 1989-12-15 | 1990-02-21 | Smith Kline French Lab | Chemical compounds |
GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
GB9114760D0 (en) | 1991-07-09 | 1991-08-28 | Pfizer Ltd | Therapeutic agents |
GB9119704D0 (en) | 1991-09-14 | 1991-10-30 | Pfizer Ltd | Therapeutic agents |
CA2079374C (en) | 1991-09-30 | 2003-08-05 | Merck Frosst Canada Incorporated | (bicyclic-azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis |
GB9121028D0 (en) | 1991-10-03 | 1991-11-13 | Pfizer Ltd | Therapeutic agents |
GB9126260D0 (en) | 1991-12-11 | 1992-02-12 | Pfizer Ltd | Therapeutic agents |
GB9213623D0 (en) | 1992-06-26 | 1992-08-12 | Pfizer Ltd | Therapeutic agents |
GB9218322D0 (en) | 1992-08-28 | 1992-10-14 | Pfizer Ltd | Therapeutic agents |
GB9311920D0 (en) | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
GB9312210D0 (en) | 1993-06-14 | 1993-07-28 | Smithkline Beecham Plc | Chemical compounds |
GB9514464D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
-
1994
- 1994-11-26 GB GB9423910A patent/GB9423910D0/en active Pending
-
1995
- 1995-10-16 WO PCT/EP1995/004066 patent/WO1996016644A1/en not_active Application Discontinuation
- 1995-10-16 JP JP8517126A patent/JP2975990B2/en not_active Ceased
- 1995-10-16 MX MX9703868A patent/MX9703868A/en not_active IP Right Cessation
- 1995-10-16 US US08/836,670 patent/US6300335B1/en not_active Expired - Lifetime
- 1995-10-16 EP EP95936507A patent/EP0793486A1/en not_active Withdrawn
-
1997
- 1997-05-23 FI FI972205A patent/FI972205A0/en not_active IP Right Cessation
-
1999
- 1999-04-13 JP JP11105626A patent/JPH11343238A/en active Pending
-
2001
- 2001-06-13 US US09/880,141 patent/US6656945B2/en not_active Expired - Lifetime
-
2003
- 2003-09-01 JP JP2003308939A patent/JP2004091490A/en active Pending
- 2003-10-27 US US10/694,644 patent/US20040087599A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4521421A (en) * | 1983-09-26 | 1985-06-04 | Eli Lilly And Company | Treatment of sexual dysfunction |
US5436233A (en) * | 1992-07-15 | 1995-07-25 | Ono Pharmaceutical Co., Ltd. | 4-aminoquinazoline derivatives |
US6656945B2 (en) * | 1994-11-26 | 2003-12-02 | Pfizer Inc | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one cGMP-PDE inhibitors for the treatment of erectile dysfunction |
US6723719B1 (en) * | 1997-04-25 | 2004-04-20 | Pfizer Inc | Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′—monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction |
US6407114B1 (en) * | 1998-10-23 | 2002-06-18 | Pfizer Inc. | Pyrazolopyrimidinone CGMP PDE5 inhibitors for the treatment of sexual dysfunction |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070010450A1 (en) * | 2003-06-13 | 2007-01-11 | Microbia, Inc., A Massachusetts Corporation | Methods and compositions for the treatment of gastrointestinal disorders |
US20100234301A1 (en) * | 2003-06-13 | 2010-09-16 | Ironwood Pharmaceuticals, Inc. | Methods and Compositions for the Treatment of Gastrointestinal Disorders |
US8101579B2 (en) | 2003-06-13 | 2012-01-24 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US9840536B2 (en) | 2003-06-13 | 2017-12-12 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
Also Published As
Publication number | Publication date |
---|---|
FI972205A (en) | 1997-05-23 |
MX9703868A (en) | 1997-09-30 |
US20010044441A1 (en) | 2001-11-22 |
EP0793486A1 (en) | 1997-09-10 |
JPH09512834A (en) | 1997-12-22 |
US6656945B2 (en) | 2003-12-02 |
JP2975990B2 (en) | 1999-11-10 |
JPH11343238A (en) | 1999-12-14 |
US6300335B1 (en) | 2001-10-09 |
WO1996016644A1 (en) | 1996-06-06 |
JP2004091490A (en) | 2004-03-25 |
FI972205A0 (en) | 1997-05-23 |
GB9423910D0 (en) | 1995-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6300335B1 (en) | 4-aminoquinazoline derivative cGMP-PDE inhibitors for the treatment of erectile dysfunction | |
US6534511B1 (en) | Bicyclic heterocyclic compounds for the treatment of impotence | |
RU2130776C1 (en) | Pyrazolepyrimidinones for treatment of impotents | |
US20030134861A1 (en) | Transmucosal phosphodiesterase inhibitors for the treatment of erectile dysfunction | |
JP2008546786A (en) | Rapidly absorbable oral formulation of PDE5 inhibitor | |
SK13232002A3 (en) | Use of pyrido[3,2-e]-pyrazinones as inhibitors of phosphodiesterase 5 for treating erectile dysfunction | |
US6465465B1 (en) | Process for the treatment of erectile dysfunction and product therefor | |
CA2203379C (en) | Cgmp-pde inhibitors for the treatment of erectile dysfunction | |
US20110224178A1 (en) | Composition and method for treating erectile dysfunction | |
KR20020095469A (en) | Use of pyrido[3,2-e]-pyrazinones as inhibitors of phosphodiesterase 5 for treating erectile dysfunction | |
MXPA00009614A (en) | Combination effective for the treatment of impotence comprising a potassium-channel-opener and a cgmp elevator |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |